Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer

The development of acute hypomagnesemia following cisplatin administration is a well-recognized complication associated with the use of this chemotherapeutic agent. However, there is limited information available in the medical literature concerning how long this abnormality may persist following th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and clinical oncology 1991-01, Vol.117 (2), p.89-90
Main Authors: MARKMAN, M, ROTHMAN, R, REICHMAN, B, HAKES, T, LEWIS, J. L, RUBIN, S, JONES, W, ALMADRONES, L, HOSKINS, W
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cisplatin - adverse effects
Drug toxicity and drugs side effects treatment
Female
Humans
Magnesium - blood
Medical sciences
Miscellaneous (drug allergy, mutagens, teratogens...)
Ovarian Neoplasms - complications
Ovarian Neoplasms - drug therapy
Pharmacology. Drug treatments
Retrospective Studies
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The development of acute hypomagnesemia following cisplatin administration is a well-recognized complication associated with the use of this chemotherapeutic agent. However, there is limited information available in the medical literature concerning how long this abnormality may persist following the discontinuation of cisplatin. Of 13 patients with ovarian cancer who had a baseline serum magnesium determination obtained prior to the initiation of a second-line cisplatin-based chemotherapy regimen, 9 (69%) were found to be hypomagnesemic (serum magnesium less than 1.4 mg/l), including 3 patients with serum magnesium values less than 1.0 mequiv/l. The median cisplatin-free interval for these 9 patients was 19 months (range 6-40 months). We conclude that persistent, and possibly permanent, hypomagnesemia is common following cisplatin chemotherapy.
ISSN:0171-5216
1432-1335
DOI:10.1007/BF01613129